Eagle Pharmaceuticals (NASDAQ:EGRX) Price Target Lowered to $31.00 at Piper Sandler

Eagle Pharmaceuticals (NASDAQ:EGRX – Get Rating) had its price target cut by Piper Sandler from $41.00 to $31.00 in a research report released on Tuesday, The Fly reports.

Separately, StockNews.com raised Eagle Pharmaceuticals from a hold rating to a buy rating in a report on Tuesday, February 21st.

Eagle Pharmaceuticals Stock Up 0.4 %

Shares of NASDAQ EGRX opened at $25.62 on Tuesday. Eagle Pharmaceuticals has a 12 month low of $23.87 and a 12 month high of $52.22. The company has a current ratio of 1.52, a quick ratio of 0.99 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $333.57 million, a price-to-earnings ratio of 13.34 and a beta of 0.92. The business has a 50-day moving average of $30.48 and a 200-day moving average of $31.00.

Institutional Trading of Eagle Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Point72 Hong Kong Ltd purchased a new stake in Eagle Pharmaceuticals in the second quarter worth approximately $34,000. Quantbot Technologies LP purchased a new stake in Eagle Pharmaceuticals in the third quarter worth approximately $44,000. Point72 Middle East FZE purchased a new stake in Eagle Pharmaceuticals in the fourth quarter worth approximately $53,000. Denali Advisors LLC purchased a new stake in Eagle Pharmaceuticals in the fourth quarter worth approximately $58,000. Finally, Teachers Retirement System of The State of Kentucky purchased a new stake in Eagle Pharmaceuticals in the third quarter worth approximately $79,000. Hedge funds and other institutional investors own 88.09% of the company’s stock.

About Eagle Pharmaceuticals

(Get Rating)

Eagle Pharmaceuticals, Inc is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. Its products include RYANODEX, BENDEKA and BELRAPZO. The company was founded by Scott L.